Recent results and analysis of transoral endoscopic thyroidectomy vestibular approach combined with 131I for differentiated thyroid cancer(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2022年第12期
- Page:
- 1563-1568
- Research Field:
- 医学生物物理
- Publishing date:
Info
- Title:
- Recent results and analysis of transoral endoscopic thyroidectomy vestibular approach combined with 131I for differentiated thyroid cancer
- Author(s):
- XU Weihong1; MEI Feng2; LI Qiang1
- 1. Department of Thyroid Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China 2. the Second Department of Surgery, Zhongshan Dongfeng Peoples Hospital, Zhongshan 528425, China
- Keywords:
- Keywords: differentiated thyroid cancer Transoral endoscopic thyroidectomy vestibular approach Radioactive iodine 131
- PACS:
- R736.1；R817.8
- DOI:
- DOI:10.3969/j.issn.1005-202X.2022.12.017
- Abstract:
- Abstract: Objective To investigate the feasibility, safety and efficacy of Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) in the treatment of differentiated thyroid cancer (DTC). Methods The clinical data of 80 patients with DTC who were admitted to Zhujiang Hospital, Southern Medical University and Zhongshan Dongfeng Peoples Hospital from July 2018 to May 2019 were retrospectively analyzed. According to the treatment protocol, they were divided into the control group (46 cases, receiving TOETVA combined with 131Ⅰ treatment) and the study group (34 cases, receiving TOETVA combined with levothyroxine tablets treatment). The therapeutic effects, thyroid index, serum cluster of differentiation 44 variant 6(CD44V6), soluble interleukin -2 receptor (sIL-2R) levels, expression of cell apoptosis signal receptor (Fas) and cycline (cycline) proteins, salivary gland function and short-term and medium-term prognosis of the two groups were compared. Results The total effective rate of treatment in the research group was 82.35%, which was higher than that in the control group (58.70%) (P<0.05). The levels of thyroglobulin antibody (TgAb), thyroid-stimulating hormone (TSH), and thyroglobulin (Tg) were all lower than those of the control group (P<0.05). After treatment, the levels of serum CD44V6, sIL-2R and Cycline protein in the treatment group were lower than those of the control group, and the expression level of serum Fas protein in the treatment group was higher than that of the control group (P<0.05). The SRs of the right submandibular gland, left submandibular gland, right parotid gland and left parotid gland before and after treatment in the research group were not significantly different from those in the control group (P>0.05). The disease-free survival rate (91.18%) in the research group within two years of follow-up was higher than that in the control group (71.74%) (P<0.05). The recurrence rate (2.94%) and metastasis rate (8.82%) in the study group within two years of follow-up were not significantly different from those in the control group (13.04% and 21.74%) (P>0.05).Conclusion TOETVA combined with 131Ⅰ therapy can help to improve the clinical effect of DTC, improve the thyroid indexes of patients, inhibit the proliferation and metastasis of malignant cells, and increase recent local control rates. There is no significant effect on the salivary gland function of patients.
Last Update: 2022-12-23